1-4 of 4
Anesh Panchal, BSc, MSc
Close
Sort by
Journal Articles

Longitudinal Mutational Analysis in Hydroxycarbamide-Resistant/Intolerant Essential Thrombocythemia Treated on the Majic-ET Study

Jennifer O'Sullivan, MB BCh BAO, Angela Hamblin, MD PhD, Anesh Panchal, BSc, MSc, Christina Yap, MSci, PhD CStat, Sonia Fox, BSc, Samah Alimam, DHSC, MD, Helene Marie-Pierre Dreau, Kieran Howard, Pauline Ware, Samantha Baker, Nicholas C.P. Cross, Mary Frances McMullin, MD, Claire N. Harrison, MD DM, FRCP, PRCPath, Adam J. Mead, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1784.
https://doi.org/10.1182/blood-2018-99-118220
Published: 2018
Journal Articles

Reduced Intensity Stem Cell Transplantation Followed By Adjunctive Lenalidomide Is Tolerable and Safe and Improves Complete Response Rate in Multiple Myeloma:a UK NCRI Phase 2 Feasibility Study (LenaRIC)

Mark Cook, MBChB,PhD, Anesh Panchal, BSc, MSc, Kristian Brock, MSc, BSc, Grant McQuaker, MD, John A. Snowden, MD, Charles R Crawley, Hannah Hunter, MB,FRCPath,MRCP, James D Cavenagh, Mirjana Sirovica, BSc(Hons), MSc, Andrea Hodgkinson, BSc(Hons),PhD, Gordon Cook, MD PhD FRCP, FRCPath
Journal: Blood
Blood (2017) 130 (Supplement 1): 3308.
https://doi.org/10.1182/blood.V130.Suppl_1.3308.3308
Published: 2017
Journal Articles

A Phase II Study to Determine the Safety and Efficacy of the Dual m-TORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination with Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Toby A. Eyre, MBBChir, MRCP, Catherine Hildyard, MRCP, BA, Anesh Panchal, BSc, MSc, Aimee E Houlton, BSc, MSc, Louise Hopkins, BSc, MRes, Angela Hamblin, MD PhD, Kim Linton, MBChB PhD, Andrew Pettitt, FRCPath, PhD, Simon Rule, MD, Kate Cwynarski, PhD MD, Sally Barrington, MBBS, MSc, FRCP, FRCR, MD, David Wrench, MA, MBBChir, FRCPath, PhD, Andrew Davies, PhD, Graham Collins, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5210.
https://doi.org/10.1182/blood.V130.Suppl_1.5210.5210
Published: 2017
Journal Articles

Correlation Between Treatment Outcomes, Baseline Characteristics and Molecular Responses in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Essential Thrombocythemia

Claire N. Harrison, DM, FRCP, FRCPath, Adam Mead, MD PhD, Sonia Fox, Anesh Panchal, BSc, MSc, Christina Yap, BSc, MSc, PhD, Aimee E Houlton, BSc, MSc, Samah Aliman, Joanne C Ewing, PhD BMBS, BSc, FRPATH,, Marion Wood, FRCP, FRCPath, Frederick Chen, MBBS, PhD FRCPath, Jason Coppell, Nicki Panoskaltsis, MD PhD, Steven Knapper, Sahra Ali, FRCPath, Angela Hamblin, MDPhD, Robyn M. Scherber, MD MPH, Holly Geyer, MD, Allison H Scotch, MD MPH, Amylou Constance Dueck, PhD, Nicholas CP Cross, PhD, Ruben A. Mesa, MD, Mary Frances McMullin, MD
Journal: Blood
Blood (2016) 128 (22): 1929.
https://doi.org/10.1182/blood.V128.22.1929.1929
Published: 2016